These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 30119215)

  • 41. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.
    Bektas M; Johnson SP; Poe WE; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1053-8. PubMed ID: 19597728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Mechanism of temozolomide-induced anti-tumor effects on glioblastoma cells in vitro is via ROS-dependent SIRT1 signaling pathway].
    Jiang Y; Sun Y; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):734-8. PubMed ID: 23291065
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling.
    Zeng H; Yang Z; Xu N; Liu B; Fu Z; Lian C; Guo H
    Cell Death Dis; 2017 Jun; 8(6):e2885. PubMed ID: 28617438
    [TBL] [Abstract][Full Text] [Related]  

  • 44. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
    Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
    Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.
    Fan TY; Wang H; Xiang P; Liu YW; Li HZ; Lei BX; Yu M; Qi ST
    Int J Clin Exp Pathol; 2014; 7(10):6662-70. PubMed ID: 25400745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
    Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
    J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide.
    Sun S; Lee D; Lee NP; Pu JK; Wong ST; Lui WM; Fung CF; Leung GK
    J Neurooncol; 2012 Sep; 109(3):467-75. PubMed ID: 22763762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment.
    Kuo YY; Ho KH; Shih CM; Chen PH; Liu AJ; Chen KC
    Life Sci; 2022 Nov; 309():121023. PubMed ID: 36202175
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
    Gao YT; Chen XB; Liu HL
    Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma.
    Liu B; Zhou J; Wang C; Chi Y; Wei Q; Fu Z; Lian C; Huang Q; Liao C; Yang Z; Zeng H; Xu N; Guo H
    Cell Death Dis; 2020 May; 11(5):384. PubMed ID: 32439916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
    Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z
    Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H; Lin H; Zhang X; Li J
    Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heat Shock Factor 1 Depletion Sensitizes A172 Glioblastoma Cells to Temozolomide via Suppression of Cancer Stem Cell-Like Properties.
    Im CN; Yun HH; Lee JH
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241425
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27.
    Sang DP; Li RJ; Lan Q
    Acta Pharmacol Sin; 2014 Jun; 35(6):832-8. PubMed ID: 24902789
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
    Yu F; Li G; Gao J; Sun Y; Liu P; Gao H; Li P; Lei T; Chen Y; Cheng Y; Zhai X; Sayari AJ; Huang H; Mu Q
    Cell Prolif; 2016 Apr; 49(2):195-206. PubMed ID: 26923184
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).
    Choi J; Lee JH; Koh I; Shim JK; Park J; Jeon JY; Yun M; Kim SH; Yook JI; Kim EH; Chang JH; Kim SH; Huh YM; Lee SJ; Pollak M; Kim P; Kang SG; Cheong JH
    Oncotarget; 2016 Oct; 7(40):65643-65659. PubMed ID: 27582539
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.